Potent, ATP-competitive Aurora kinase inhibitor (IC50 values are 3, 9 and 31 nM for Aurora C, A and B, respectively). Exhibits both in vitro and in vivo activity against human cancer cell lines and tumor xenograft models. Displays additive antiproliferative effects in combination with chemotherapeutics such as carboplatin (Cat. No. 2626), gemcitabine (Cat. No. 3259) and 5-fluorouracil (Cat. No. 3257). Purity 98%. MW (observed): 527.04